Combined chemotherapy of irinotecan and low‐dose cisplatin (I/low‐P) against metastatic biliary tract cancer

There is no established or effective standard therapy for metastatic biliary tract cancer, resulting in poor prognosis. Recently, we performed combination chemotherapy of irinotecan and low‐dose cisplatin (I/low‐P) for three consecutive patients with metastatic biliary tract cancer. The regimen of I/low‐P therapy consisted of irinotecan (60 mg/m2) and low‐dose cisplatin (6 mg/m2), administered by intravenous infusion weekly or biweekly. Of the three patients, two showed a partial response, with durations of more than 20 months, and 2 months, respectively, while the third patient had stable disease for 3 months. One patient, who had jaundice, had grade 3 thrombocytopenia, but the other patients did not have any severe toxicities. Survival times were more than 20 months, 10 months, and 13 months, respectively. These outcomes suggest that I/low‐P therapy is safe and may be worth trying as a first‐line chemotherapy for patients with metastatic biliary tract cancer.